[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342004-105":59,"doc-detail-342004-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","incidence-of-hematologic-cancer-types-in-japan-by-icd-o-3-code-analysis-of-national-cancer-registry","Incidence of hematologic cancer types in Japan by ICD-O-3 code - analysis of National Cancer Registry","","This research classifies hematologic cancer subtypes in Japan’s National Cancer Registry (NCR) in 2016 using ICD-O-3 codes and compares case counts with the Japanese Society of Hematology’s Blood Diseases Registry (BDR). NCR reported 67,919 hematologic cancer cases, including diffuse large B-cell lymphoma (11.07 per 100,000) and plasma cell myeloma (5.26 per 100,000). ICD-O-3 coding identified 12,365 additional cases beyond publicly reported numbers, highlighting the need for accurate updates for medical resource planning.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/incidence-of-hematologic-cancer-types-in-japan-by-icd-o-3-code-analysis-of-national-cancer-registry/342004/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/incidence-of-hematologic-cancer-types-in-japan-by-icd-o-3-code-analysis-of-national-cancer-registry/342004.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data sources are used to study hematologic cancer incidence in Japan?","Question",{"text":112,"@type":113},"The study uses individual-level data from Japan’s National Cancer Registry (NCR) and compares counts with the Japanese Society of Hematology’s Blood Diseases Registry (BDR).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does ICD-O-3 coding affect the analysis of cancer incidence?",{"text":117,"@type":113},"ICD-O-3 codes categorize tumors by site and histology, enabling more detailed subtype classification than broad ICD reporting. The study finds ICD-O-3 revealed 12,365 additional cases beyond publicly reported numbers.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the main practical implication of the findings?",{"text":121,"@type":113},"Accurately updated ICD-O-3–based incidence data are necessary for medical resource planning and for better estimation of future patient numbers by subtype.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342004,1790153990,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE     \nIncidence of hematologic cancer types in Japan by ICD-O-3 code: analysis of National Cancer Registry  \nAyako Muramatsu* , a and Tetsuji Kawakamia  \naSynix Inc., Tokyo, Japan  \nABSTRACT  \nAim: We classified subtypes of hematologic cancer in Japan’s National Cancer Registry (NCR) in 2016 by ICD-O-3 code and compared numbers with the Japanese Society of Hematology’s Blood Diseases Registry (BDR) .  \nMaterials & methods: We reviewed data for individual cases, and calculated incidence per 100,000 . Results: NCR reported 67,919 cases of hematological cancer, including diffuse large B-cell lymphoma, Not Otherwise Specified (NOS) (11.07 per 100,000), plasma cell myeloma (5.26/100,000), myelodysplastic syndrome, NOS (3.92/100,000), malignant lymphoma, NOS (3.03/100,000), marginal zone B-cell lymphoma, NOS (2.52/100,000) and follicular lymphoma, grade 1 (1.43/100,000). Around 48% of NCR cancers were also reported in the Blood Diseases Registry.  \nConclusion: ICD-O-3 codes revealed 12,365 additional cases to the 55,554 reported publicly. Accurately updated data are necessary for medical resource planning.  \nPLAIN LANGUAGE SUMMARY  \nJapan’s National Cancer Registry started in 2016, when 157 hematologic cancer subtypes and 67,919 cases (males: 37,916; females: 30,003) were reported, giving a cancer case incidence of 53.51 per 100,000 . The most common hematologic cancers were diffuse large B-cell lymphoma, NOS (11.07 per 100,000), plasma cell myeloma (5.26 per 100,000) and myelodysplastic syndrome, NOS (3.92 per 100,000) . Incidence data under ICD-O-3 by age and sex revealed different patterns among subtypes, allowing more accurate estimation of future patient numbers. This in turn allows grouping of indications to suit clinical needs, and aids pharmaceutical companies in understanding patient populations for new drugs.  \nARTICLE HISTORY  \nReceived 7 December 2023 Accepted 30 September 2024  \nKEYWORDS  \nblood diseases registry; hematologic cancer;japan; national cancer registry; rare cancer  \n1. Introduction  \nThe ICD-O-3 code was specifically designed to categorize tumors and is primarily used in tumor or cancer registries to code the site (topography) and histology (morphology) of neoplasms, usually as obtained from pathology reports and research, what brings advantages over the traditional ICD codes, that in most cases reports only one of them (topography or histology). The ICD-O-3 was developed by a joint group of the WHO and the International Agency for Research on Cancer in 2000 and revised again 2011 to the ICD-O-3.1. This version is currently used by cancer registries globally, including the NCR in Japan. The NCR was established in 2016 as a key element of the Cancer Control Act of Japan, and reporting of all diagnosed cases to the NCR system is now a legal requirement for medical institutions across the country [1,2] . This allows an understanding of the actual incidence of diagnosed cancers in Japan in place of estimates. Specific data in  \nthe NCR include incidence by age, sex and ICD-O-3 code. Since 2019, NCR individual data have been accessible for public use.  \nThe incidence of hematologic cancers in Japan was reported from 1975 until 2015 by the Regional Cancer Registry, and then from 2016 by the National Cancer Registry (NCR) [1–3]. Publicly, however, these registries report hematologic cancers in three broad categories only, namely malignant lymphoma (ICD-10: C81-C85, C96), multiple myeloma (ICD-10: C88-C90) and leukemia (ICD- 10: C91-C95) [2–4] . These data lack sufficient detail for pharmaceutical companies aiming to understand patient numbers for clinical trial design, resource allocation and other purposes in the development of new treatment options. This is particularly important given that drugs for cancer treatment are selected by specific cancer type, necessitating an understanding of incidence by detailed cancer subtype. Although several previous studies have  \nCONTACT Ayako Muramatsu Tel.: +","cbCaikagjxLQIfAC","https://ap.wps.com/l/cbCaikagjxLQIfAC","pdf",663317,"English","# Introduction\n## Background on ICD-O-3 and cancer registries\n# Materials & methods\n## Data sources\n## Analysis approach\n# Results\n## Overall incidence by ICD-O-3 subtype\n## Comparison with BDR\n# Conclusion","[{\"question\":\"What data sources are used to study hematologic cancer incidence in Japan?\",\"answer\":\"The study uses individual-level data from Japan’s National Cancer Registry (NCR) and compares counts with the Japanese Society of Hematology’s Blood Diseases Registry (BDR).\"},{\"question\":\"How does ICD-O-3 coding affect the analysis of cancer incidence?\",\"answer\":\"ICD-O-3 codes categorize tumors by site and histology, enabling more detailed subtype classification than broad ICD reporting. The study finds ICD-O-3 revealed 12,365 additional cases beyond publicly reported numbers.\"},{\"question\":\"What is the main practical implication of the findings?\",\"answer\":\"Accurately updated ICD-O-3–based incidence data are necessary for medical resource planning and for better estimation of future patient numbers by subtype.\"}]","Incidence of hematologic cancer types in Japan by ICD-O-3 code - analysis of National Cancer Registry | PDF",1790044717,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98c0bcb2e6a1c10b49873352ae9250c4.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1122a6654c5110e33c16e6641920e0f.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9eacfcfd5050234a9817146041fbb58.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b234c01a24ef5f0d642b91fccc89a0e3.webp",980,1268]